R&D Harnessing the cell's own degradation machinery, with Benedi... Benedict Cross, Chief Technology Officer at PhoreMost, discusses targeted protein degradation.
R&D Targeting proteins to bring new medicines to patients with f... In a new pharmaphorum podcast, editor-in-chief Jonah Comstock speaks with Dr Victoria Richon, CEO of Entact Bio, a company focused on the small molecule space, with its team of scientists,
Events Partner Content 5th Annual Targeted Protein Degradation Summit Deliver Next Generation Degraders to Patients Faster
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
